nach oben

Erschienen in:

29.04.2021 | Prävention und Rehabilitation in der Kardiologie | CME

Sekundärprävention nach TIA oder ischämischem Schlaganfall

verfasst von: Prof. Dr. Hans Christoph Diener, Prof. Dr. Georg Nickenig

Erschienen in: Herz | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der Schlaganfall ist eine der Hauptursachen von Mortalität und bleibenden Behinderungen. Daher kommt der Sekundärprävention des rezidivierenden Schlaganfalls eine hohe Priorität zu. Die Sekundärprävention des ischämischen Schlaganfalls umfasst die Optimierung des Lebensstils und der Ernährung, die Behandlung von Risikofaktoren wie Bluthochdruck, Diabetes mellitus und Hyperlipidämie, die Rezidivprophylaxe mit Thrombozytenaggregationshemmern bei Patienten mit hohem Gefäßrisiko und die Antikoagulation bei Vorhofflimmern. Zusätzlich dienen Karotisoperation oder Stenting bei ausgewählten symptomatischen Patienten und der Verschluss eines offenen Foramen ovale nach kryptogenem Schlaganfall der Sekundärprävention.

Coull AJ, Lovett JK, Rothwell PM et al (2004) Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328:326PubMedPubMedCentralCrossRef

Mohan KM, Wolfe CD, Rudd AG et al (2011) Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 42:1489–1494PubMedCrossRef

Amarenco P, Lavallee PC, Monteiro Tavares L et al (2018) Five-year risk of stroke after TIA or minor ischemic stroke. N Engl J Med 378:2182–2190PubMedCrossRef

Rothwell PM, Giles MF, Chandratheva A et al (2007) Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 370:1432–1442PubMedCrossRef

Diener HC, Hankey GJ (2020) Primary and secondary prevention of Ischemic stroke and cerebral hemorrhage: JACC focus seminar. J Am Coll Cardiol 75:1804–1818PubMedCrossRef

Xie X, Atkins E, Lv J et al (2016) Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387:435–443PubMedCrossRef

Kitagawa K, Yamamoto Y, Arima H et al (2019) Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol 76:1309–1318PubMedPubMedCentralCrossRef

Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104PubMedCrossRef

Andrew NE, Kim J, Thrift AG et al (2018) Prescription of antihypertensive medication at discharge influences survival following stroke. Neurology 90:e745–e753PubMedCrossRef

10.

Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22CrossRef

11.

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (Sparcl) Investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549–559CrossRef

12.

Paciaroni M, Hennerici M, Agnelli G et al (2007) Statins and stroke prevention. Cerebrovasc Dis 24:170–182PubMedCrossRef

13.

Goldstein LB, Amarenco P, Szarek M et al (2008) Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology 70:2364–2370PubMedCrossRef

14.

Ziff OJ, Banerjee G, Ambler G et al (2019) Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 90:75–83PubMedCrossRef

15.

Amarenco P, Labreuche J (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8:453–463PubMedCrossRef

16.

Amarenco P, Kim JS, Labreuche J et al (2020) A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 382:9PubMedCrossRef

17.

Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188PubMedCrossRef

18.

Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722PubMedCrossRef

19.

Schwartz GG, Steg PG, Szarek M et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379:2097–2107PubMedCrossRef

20.

Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772PubMedCrossRef

21.

Lee M, Saver JL, Liao HW et al (2017) Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. Stroke 48:388–393PubMedCrossRef

22.

North EJ, Newman JD (2019) Review of cardiovascular outcomes trials of sodium-glucose cotransporter‑2 inhibitors and glucagon-like peptide‑1 receptor agonists. Curr Opin Cardiol 34:687–692PubMedPubMedCentralCrossRef

23.

Bellastella G, Maiorino MI, Longo M et al (2020) Glucagon-like peptide‑1 receptor agonists and prevention of stroke systematic review of cardiovascular outcome trials with meta-analysis. Stroke 51:666–669PubMedCrossRef

24.

Toole JF, Malinow MR, Chambless LE et al (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 291:565–575PubMedCrossRef

25.

Vitatops Trial Study Group (2010) B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 9:855–865CrossRef

26.

Hankey GJ, Eikelboom JW, Yi Q et al (2012) Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol 11:512–520PubMedPubMedCentralCrossRef

27.

Viscoli CM, Brass LM, Kernan WN et al (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243–1249PubMedCrossRef

28.

Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 524:71–86CrossRef

29.

Johnston SC, Amarenco P, Albers GW et al (2016) Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 375:35–43PubMedCrossRef

30.

Amarenco P, Albers GW, Denison H et al (2017) Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol 16:301–310PubMedCrossRef

31.

Kennedy J, Hill MD, Ryckborst KJ et al (2007) Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 6:961–969PubMedCrossRef

32.

Wang Y, Wang Y, Zhao X et al (2013) Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369:11–19PubMedCrossRef

33.

Johnston SC, Easton JD, Farrant M et al (2018) Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 379:215–225PubMedPubMedCentralCrossRef

34.

Prasad K, Siemieniuk R, Hao Q et al (2018) Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. BMJ 363:k5130PubMedCrossRef

35.

Johnston SC, Amarenco P, Denison H et al (2020) Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 383:207–217PubMedCrossRef

36.

Algra A, van Gijn J (1999) Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 65:255CrossRef

37.

Caprie Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339CrossRef

38.

Diener HC, Bogousslavsky J, Brass LM et al (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364:331–337PubMedCrossRef

39.

Bhatt DL, Fox KA, Hacke W et al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706–1717PubMedCrossRef

40.

Benavente OR, Hart RG, Mcclure LA et al (2012) Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 367:817–825PubMedCrossRef

41.

European Atrial Fibrillation Trial (Eaft) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255–1262CrossRef

42.

Saxena R, Koudstaal PJ (2004) Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Stroke 35:1782–1783CrossRef

43.

Connolly S, Pogue J, Hart R et al (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 367:1903–1912PubMedCrossRef

44.

Ntaios G, Papavasileiou V, Diener HC et al (2017) Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 12:589–596PubMedCrossRef

45.

Mizoguchi T, Tanaka K, Toyoda K et al (2020) Early initiation of direct oral anticoagulants after onset of stroke and short- and long-term outcomes of patients with nonvalvular atrial fibrillation. Stroke 51:883–891PubMedCrossRef

46.

Paciaroni M, Agnelli G, Ageno W et al (2016) Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. Thromb Haemost 116:410–416PubMedCrossRef

47.

Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962PubMedCrossRef

48.

Diener H‑C, Hankey GJ, Easton JD et al (2020) Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 22:I13–I21PubMedPubMedCentralCrossRef

49.

Adams HP Jr., Bendixen BH, Kappelle LJ et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 24:35–41PubMedCrossRef

50.

Hart RG, Diener HC, Coutts SB et al (2014) Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 13:429–438PubMedCrossRef

51.

Diener HC, Sacco RL, Easton JD et al (2019) Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 380:1906–1917PubMedCrossRef

52.

Hart RG, Sharma M, Mundl H et al (2018) Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 378:2191–2201PubMedCrossRef

53.

Hagen PT, Scholz DG, Edwards WD (1984) Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 59:17–20PubMedCrossRef

54.

Furlan AJ, Reisman M, Massaro J et al (2012) Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 366:991–999PubMedCrossRef

55.

Carroll JD, Saver JL, Thaler DE et al (2013) Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 368:1092–1100PubMedCrossRef

56.

Meier B, Kalesan B, Mattle HP et al (2013) Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 368:1083–1091PubMedCrossRef

57.

Mas JL, Derumeaux G, Guillon B et al (2017) Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 377:1011–1021PubMedCrossRef

58.

Saver JL, Carroll JD, Thaler DE et al (2017) Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 377:1022–1032PubMedCrossRef

59.

Sondergaard L, Kasner SE, Rhodes JF et al (2017) Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 377:1033–1042PubMedCrossRef

60.

Mir H, Siemieniuk RAC, Ge LC et al (2018) Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence. BMJ Open 8:e23761PubMedPubMedCentralCrossRef

61.

Diener HC, Grau AJ et al (2018) Kryptogener Schlaganfall und offenes Formaen ovale: S2e Leitlinie. Nervenarzt 89:1143–1153PubMedCrossRef

62.

Orrapin S, Rerkasem K (2017) Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev 6:CD1081PubMed

63.

Rothwell PM, Warlow CP (1999) Prediction on benefit from carotid endarterectomy in individual patients: a risk-modelling study. Lancet 353:2105–2110PubMedCrossRef

64.

Bonati LH, Dobson J, Featherstone RL et al (2015) Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the international carotid stenting study (ICSS) randomised trial. Lancet 385:529–538PubMedPubMedCentralCrossRef

65.

Bonati LH, Lyrer P, Ederle J et al (2012) Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev 9:CD515

66.

Brott TG, Howard G, Roubin GS et al (2016) Long-term results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med 374:1021–1031PubMedPubMedCentralCrossRef

Titel: Sekundärprävention nach TIA oder ischämischem Schlaganfall
verfasst von: Prof. Dr. Hans Christoph Diener
Prof. Dr. Georg Nickenig
Publikationsdatum: 29.04.2021
Verlag: Springer Medizin
Schlagwörter: Prävention und Rehabilitation in der Kardiologie
Hypertonie
Diabetes mellitus
Thrombozytenaggregationshemmer
Embolieprophylaxe und Antikoagulation
Karotisstenose
Arterielle Hypertonie
Hypercholesterinämie
Apoplex
Erschienen in: Herz / Ausgabe 3/2021
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-021-05035-0

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Cardiovascular evaluation in advanced chronic kidney disease

Serum osteoprotegerin level is independently related to subclinical left atrial mechanical function in patients with hypertension and diabetes

Erratum to: Left ventricular systolic dysfunction in patients with unprotected left main coronary artery disease

Real-world analysis of a Biolimus A9 polymer-free drug-coated stent with very short dual antiplatelet therapy in patients at high bleeding risk

Prognostic value of fragmented QRS complex in patients with acute myocardial infarction

Effect of Ginkgo biloba extract on pacemaker channels encoded by HCN gene